Molecular Partners AG MOLN Stock
Molecular Partners AG Price Chart
Molecular Partners AG MOLN Financial and Trading Overview
Molecular Partners AG stock price | 3.57 USD |
Previous Close | 6.82 USD |
Open | 6.8 USD |
Bid | 0 USD x 900 |
Ask | 0 USD x 1200 |
Day's Range | 6.62 - 6.82 USD |
52 Week Range | 5.5 - 8 USD |
Volume | 3.29K USD |
Avg. Volume | 1.45K USD |
Market Cap | 243.38M USD |
Beta (5Y Monthly) | 0.622988 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.81 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 14.61 USD |
MOLN Valuation Measures
Enterprise Value | -8387386 USD |
Trailing P/E | N/A |
Forward P/E | -4.272152 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 12.250671 |
Price/Book (mrq) | 0.98915595 |
Enterprise Value/Revenue | -0.422 |
Enterprise Value/EBITDA | 0.167 |
Trading Information
Molecular Partners AG Stock Price History
Beta (5Y Monthly) | 0.622988 |
52-Week Change | 1.19% |
S&P500 52-Week Change | 20.43% |
52 Week High | 8 USD |
52 Week Low | 5.5 USD |
50-Day Moving Average | 6.54 USD |
200-Day Moving Average | 6.43 USD |
MOLN Share Statistics
Avg. Volume (3 month) | 1.45K USD |
Avg. Daily Volume (10-Days) | 1.79K USD |
Shares Outstanding | 36.06M |
Float | 14.42M |
Short Ratio | 3.54 |
% Held by Insiders | 0% |
% Held by Institutions | 2.63% |
Shares Short | 3.53K |
Short % of Float | N/A |
Short % of Shares Outstanding | 0.010% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -251.93% |
Operating Margin (ttm) | -256.85% |
Gross Margin | -146.49% |
EBITDA Margin | -252.44% |
Management Effectiveness
Return on Assets (ttm) | -11.46% |
Return on Equity (ttm) | -20.57% |
Income Statement
Revenue (ttm) | 19.87M USD |
Revenue Per Share (ttm) | 0.61 USD |
Quarterly Revenue Growth (yoy) | -98.20% |
Gross Profit (ttm) | 138.85M USD |
EBITDA | -50153000 USD |
Net Income Avi to Common (ttm) | -50052000 USD |
Diluted EPS (ttm) | -1.69 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 232.37M USD |
Total Cash Per Share (mrq) | 7.14 USD |
Total Debt (mrq) | 4.55M USD |
Total Debt/Equity (mrq) | 2.05 USD |
Current Ratio (mrq) | 15.443 |
Book Value Per Share (mrq) | 6.824 |
Cash Flow Statement
Operating Cash Flow (ttm) | -61540000 USD |
Levered Free Cash Flow (ttm) | -38268500 USD |
Profile of Molecular Partners AG
Country | United States |
State | N/A |
City | Schlieren |
Address | Wagistrasse 14 |
ZIP | 8952 |
Phone | 41 44 755 77 00 |
Website | https://www.molecularpartners.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 175 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Q&A For Molecular Partners AG Stock
What is a current MOLN stock price?
Molecular Partners AG MOLN stock price today per share is 3.57 USD.
How to purchase Molecular Partners AG stock?
You can buy MOLN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Molecular Partners AG?
The stock symbol or ticker of Molecular Partners AG is MOLN.
Which industry does the Molecular Partners AG company belong to?
The Molecular Partners AG industry is Biotechnology.
How many shares does Molecular Partners AG have in circulation?
The max supply of Molecular Partners AG shares is 38.11M.
What is Molecular Partners AG Price to Earnings Ratio (PE Ratio)?
Molecular Partners AG PE Ratio is now.
What was Molecular Partners AG earnings per share over the trailing 12 months (TTM)?
Molecular Partners AG EPS is -1.81 USD over the trailing 12 months.
Which sector does the Molecular Partners AG company belong to?
The Molecular Partners AG sector is Healthcare.
Molecular Partners AG MOLN included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
- {{ link.label }} {{link}}